Soleno Therapeutics (SLNO) Among Stocks That Will Bounce Back According to Analysts

Group 1 - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is recognized by Wall Street analysts as one of the stocks expected to bounce back, with LifeSci Capital reiterating a Buy rating and a price target of $110 [1] - Piper Sandler has identified Soleno Therapeutics as a commercial-stage biotech company poised for transformational growth in 2026, following insights gained from discussions at a Healthcare Conference [2][3] - The company has a solid plan for drug launches and progress, which has led to improved confidence from analysts [3] Group 2 - On January 5, Soleno Therapeutics announced pivotal study results for VYKAT XR, published in the Journal of Clinical Endocrinology and Metabolism, which established the drug's efficacy and safety [4] - The study supports VYKAT XR's approval by the FDA as the first and only treatment for hyperphagia in individuals with Prader-Willi syndrome [4] - Soleno Therapeutics focuses on developing novel therapeutics for rare diseases, indicating a specialized market approach [5]